CAMBRIDGE, Mass. — Iterative Health has appointed Nadege Gunn, M.D., CPI, DABOM, FAASLD, as Chief Medical Officer, Hepatology and Obesity, adding a veteran physician-scientist to its senior leadership team as the company expands its focus on metabolic liver disease and obesity research.
In her new role, Dr. Gunn will provide strategic medical and scientific leadership across hepatology and obesity programs, overseeing medical affairs, development of specialized site operations, and collaboration with biopharmaceutical sponsors and contract research organization partners. The appointment supports Iterative Health’s growing portfolio in hepatology and obesity clinical research.
Dr. Gunn is a board-certified gastroenterologist, hepatologist, and obesity medicine specialist with more than 15 years of experience as a principal investigator on more than 100 early- and late-phase clinical trials. Her research spans metabolic and chronic liver diseases, including MASH and MASLD, with a focus on translating complex clinical trial protocols into effective, community-based research programs.
“Iterative Health has created an impressive foundation to advance hepatology and obesity research at scale,” said Dr. Gunn. “As a practicing physician and with experience as a principal investigator, I’m excited to join a team that is deeply focused on empowering providers and extending cutting-edge clinical research into the communities that care for these patients every day.”
Dr. Gunn currently practices at Coryell Health, where she serves as hepatology clinic director in a rural, community-based setting. She brings extensive leadership experience in clinical research operations, peer-to-peer education, and international protocol development. She is the founder and former President and CEO of Impact Research Institute in Waco, Texas, which is widely regarded as a leading hepatology research center.
Her academic experience includes teaching appointments at Texas A&M University, Dell Medical School at The University of Texas at Austin, and Baylor University. She also serves as a committee member with the Chronic Liver Disease Foundation’s Women in Hepatology: Initiatives, Sponsorship, and Empowerment program, which focuses on increasing visibility and opportunities for women in hepatology.
The appointment comes as Iterative Health continues to invest in leadership and operational growth. The company also announced the promotion of Dana Feuchtbaum from Chief Product Officer to Chief Operating Officer. In her expanded role, Feuchtbaum will oversee operations and technology development across Iterative Health’s global research site network.
“For providers and sponsors alike, Dr. Gunn strengthens the clinical leadership and operational confidence behind every hepatology and obesity study we support,” said Feuchtbaum. “Her appointment accelerates our ability to support increasingly complex hepatology and obesity trials at scale.”
If you want this tightened further for wire length, or adjusted to match the tone of a straight news brief versus a feature-style release, I can do that without touching the quotes.
